Effect of shortterm continuous subcutaneous insulin infusion treatment on serum betatrophin in newly diagnosed type 2 diabetes
HONG Xia-fei1， XUE Hao-ying1， WANG Su1， DENG Jia-liang1， MA Su-xian1， YU Shu-ping1， YANG Qi-chao2， YANG Ling1， WANG Dong1， YIN Wei1， PAN Rui-rong1， ZHOU Li-bin3， YUAN Guo-yue1
(1. Department of Endocrinology, the Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001; 2. Department of Endocrinology, the Affiliated Wujin Hospital of Jiangsu University, Changzhou Jiangsu 213002; 3. Department of Endocrinology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China）
Abstract：Objective： To investigate the effect of shortterm continuous subcutaneous insulin infusion (CSII) on serum betatrophin in patients with newly diagnosed type 2 diabetes mellitus, and to study the relationships among betatrophin, and IR, pancreatic β-cell function. Methods： Sixty patients with newly diagnosed type 2 diabetes mellitus were treated with CSII for two weeks. Oral glucose tolerance test (OGTT), insulin releasing test, blood lipid and other relevant items were measured before and after therapy. Serum betatrophin level was determined with ELISA. Results： Two weeks of CSII treatment in T2DM resulted in significant elevation in serum betatrophin［393.79(168.51-577.63) pg/mL vs. 448.83(229.89-719.68), P＜0.05］. Correlation analysis showed that the serum betatrophin before treatment was positively correlated with HbA1c（r=0.320, P＜0.05）, while negatively correlated with △Glu 0(r=-0.304, P＜0.05) and △HOMA-IR（r=-0.266, P＜0.05）. The change of serum betatrophin (△Betatrophin) was positively correlated with △Ins 0(r=0.282, P<0.05) and △C-P 0(r=0.307, P<0.05). Multiple stepwise regression analysis showed that △C-P 0 was the independent influencing factor for the △Betatrophin(β=172.03, P=0.016). Conclusion： The concentration of serum betatrophin was elevated after two weeks of CSII in newly diagnosed T2DM. The △C-P 0 was the independent related factor in the △Betatrophin.
［Key words］type 2 diabetes mellitu; continuous subcutaneous insulin infusion; Betatrophin
2016, Vol. 26 
